Health & Biotech
Check out the latest Cannabis news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Health & Biotech
Bioxyne’s revenue soars 48pc after key manufacturing licences boost growth
Health & Biotech
Health Check: Long-suffering Mesoblast investors dare to dream
Health & Biotech
Health Check: Cancer drug developer Chimeric heads to blood bank for better patient cells
Health & Biotech
AGH raises $2 million for its US cannabis beverage market expansion
Health & Biotech
Althea launches new dried medicinal cannabis flower range
Health & Biotech
Property valued at up to $12m as Melodiol secures convertible note deal
Health & Biotech
Weed Week: MDMA for PTSD hits roadblock with FDA; and recent ASX cannabis stock winners
Stockhead TV
Long Shortz with Althea Group: Why this stock is looking towards FY25
Health & Biotech
Althea aims for positive earnings after restructure, leap into US cannabis beverage market
Health & Biotech
Weed Week: It’s showtime! Cannabis could come back from the dead as US makes biggest move in 50 years
Health & Biotech
Melodiol delivers strong revenues in Q1 as US moves to reclassify cannabis
Health & Biotech
Weed Week: A VAST majority of Americans now want marijuana to be legal
Health & Biotech
Melodiol unaudited revenue up 79% in Q1 FY24
Health & Biotech
Melodiol welcomes Chuck’s petition to pass US SAFER Banking Act
Health & Biotech
Melodiol’s Mernova gains more traction in Canada: revenues increase, new products launched
Health & Biotech
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Health & Biotech
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Health & Biotech
Melodiol subsidiary Mernova expands products in six lucrative Canadian provinces
Health & Biotech
Melodiol subsidiaries deliver $2 million revenue to group in strong start to year
News
Top 10 at 10: Legal mushrooms? The party is at Bioxyne’s house
Health & Biotech
Weed Week: Medicinal cannabis will be here no matter what; and recent ASX pot winners
Health & Biotech
Bioxyne subsidiary unveils platform for transparent pricing in Australia’s B2B medical cannabis market
Health & Biotech
Weed Week: Cannabis stocks down almost 20% in 2023 but ECS Botanics showing resilience
Health & Biotech
Weed Week: Cannabis stocks down almost 20pc in 2023, but here’s why they could rebound by Q2 2024
Health & Biotech
Melodiol’s FY23 revenue exceeds $20m as acquisition strategy proves successful
Experts
Dr Boreham’s Crucible: Excessive sweater? Botanix is here to get you fit for public consumption again
Health & Biotech
Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot
Health & Biotech
Melodiol enjoys milestone 2023 as subsidiaries bank profits
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
News
ASX Small Caps Market Wrap: Which one of the seven signs of the weed apocalypse dropped this morning?
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
News
In Case You Missed It: Record monthly Canadian cannabis revenue takes top spot
News
10 at 11ish: First Au gets nod for bulk sampling at Victorian gold project
Health & Biotech
‘Current inventory moving very quickly’: Melodiol’s Canadian subsidiary continues to deliver record revenue
News
Quarterly Wrap: Pot stocks shine with record revenues for Melodiol, 75pc increase in revenue for Bioxyne
Health & Biotech
Weed Week: US House Speaker ousting could boost weed stocks; TGA urged to allow the term ‘medicinal cannabis’
Health & Biotech
Bioxyne subsidiary imports $3.2million of premium quality cannabis flower into Australia
Health & Biotech
Melodiol marks another record revenue quarter with $7.5m of unaudited sales, up 265% on the PCP
Health & Biotech
Melodiol jumps 20pc as subsidiary Health House International’s Aussie operations deliver quarterly profit
Health & Biotech
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Health & Biotech
‘Nothing short of exceptional’: Melodiol’s psychedelics subsidiary shows promising Phase II PTSD trial results
Health & Biotech
Record sales drive third straight quarter of revenue growth for Melodiol subsidiary Mernova
News
ECS Exclusive: How we pulled off the biggest cross-border pot deal in Aussie history
News
Top 10 at 11: Solid drilling results and a massive dope deal have tongues wagging today
Health & Biotech
Sales highs continue for Melodiol as it grows its Mernova footprint right across Canada
Health & Biotech
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Load More